FDA Approves DULOXETINE — ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. has announced the approval of the ANDA for duloxetine hydrochloride oral tablets, introducing a generic alternative to the branded product. This regulatory win is expected to significantly impact the market, offering a cost-effective option for patients and potentially increasing competitive pressure in the extended-release anti-depressant sector.